EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Technologies to support vaccine development against antimicrobial-resistant bacteria

Giulia Cardinali, Eleonora Nencini, Ceren Gul, Rino Rappuoli, Claudia Sala, Giampiero Batani iD

Philosophical Transactions B · 2026

DOI: 10.1098/rstb.2025.0004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Philosophical Transactions B, 2026. Verfasst von Giulia Cardinali und 5 weiteren Autor:innen. Beteiligte Einrichtung: Monoclonal Antibody Discovery (MAD) Laboratory, Fondazione Toscana Life Sciences, Siena, Tuscany53100, Italy. Hauptthemen laut MEDLINE: Vaccine Development, Bacterial Vaccines, Drug Resistance, Bacterial, Bacteria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance (AMR) represents one of the most critical global health challenges of the twenty-first century. The emergence and spread of microorganisms that no longer respond to the available antibiotics has prompted the World Health Organization to call for renewed commitment and investments in the discovery and development of novel prophylactic and therapeutic strategies. In particular, vaccines can help reduce the incidence caused by antimicrobial-resistant pathogens, thereby decreasing the need for antibiotics and the risk of selecting resistant strains. Here we describe standard and innovative approaches to vaccine design starting from live-attenuated and killed whole-cell vaccines, going through the revolution represented by Reverse Vaccinology and recombinant DNA technologies, and finally ending with rational vaccine design allowed by monoclonal antibody discovery, structural biology, nanoparticles and mRNA biology. Overall, we expect that the recent major progress in vaccinology will enhance health protection and reduce the impact of the AMR phenomenon in high-income as well as in low- and middle-income countries. This article is part of the Royal Society Science+ meeting issue ‘Vaccines and antimicrobial resistance: from science to policy’.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccine DevelopmentBacterial VaccinesDrug Resistance, BacterialBacteriaVaccinologyBacterial Infections

Stichwörter der Autor:innen

antimicrobial resistancebacteriaimmune systeminfectious diseasesvaccines

Substanzen

Bacterial Vaccines

Autor:innen und Institutionen

  • Monoclonal Antibody Discovery (MAD) Laboratory, Fondazione Toscana Life Sciences, Siena, Tuscany53100, Italy.
  • Fondazione Biotecnopolo di Siena , Siena, Tuscany53100, Italy.

ORCID-Profile: Giampiero Batani

Zitieren

APA

Cardinali, G., Nencini, E., Gul, C., Rappuoli, R., Sala, C., & Batani, G. (2026). Technologies to support vaccine development against antimicrobial-resistant bacteria. Philosophical Transactions B. https://doi.org/10.1098/rstb.2025.0004

Vancouver

Cardinali G, Nencini E, Gul C, Rappuoli R, Sala C, Batani G. Technologies to support vaccine development against antimicrobial-resistant bacteria. Philosophical Transactions B. 2026. doi:10.1098/rstb.2025.0004

BibTeX
@article{Cardinali2026,
  author = {Cardinali, Giulia and Nencini, Eleonora and Gul, Ceren and Rappuoli, Rino and Sala, Claudia and Batani, Giampiero},
  title = {Technologies to support vaccine development against antimicrobial-resistant bacteria},
  journal = {Philosophical Transactions B},
  year = {2026},
  doi = {10.1098/rstb.2025.0004}
}
Kostenlos starten →